{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-009944","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.606040+00:00","generated_at":"2026-06-15T00:49:47.068023+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ProMIS reports Q1 2023 results, FDA clears IND for Alzheimer's candidate PMN310","bullets":["FDA cleared IND for lead therapeutic candidate PMN310 for Alzheimer's disease; phase 1 enabling activities underway.","Cash and cash equivalents of $3.3M as of March 31, 2023, down from $5.9M at December 31, 2022.","Net loss of $5.0M for Q1 2023 compared to $2.1M in Q1 2022, driven by increased R&D spending on PMN310.","R&D expenses rose to $3.5M from $1.9M YoY, primarily for drug product manufacturing and IND filing costs.","Preclinical data presented at AD/PD and AAN conferences showing PMN310 selectivity and memory protection in AD models."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-009944","json":"https://secwatch.observer/filing/0001558370-23-009944.json","markdown":"https://secwatch.observer/filing/0001558370-23-009944.md","text":"https://secwatch.observer/filing/0001558370-23-009944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000155837023009944/0001558370-23-009944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000155837023009944/pmn-20230515x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T00:49:47.068023+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13043941a6b2c1541851a02cd7cfc58a7d887044","claim":"ProMIS Neurosciences Inc. reported the quarter ended March 31, 2023 results: net income $5.0 million.","evidence_excerpt":"Net loss was $5.0 million for the quarter ended March 31, 2023, compared to $2.1 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374339/000155837023009944/0001558370-23-009944-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"$5.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}